Summary
Akifumi Morinaka is a biotech executive and entrepreneur with over a decade of experience translating iPSC biology and translational science into medicines and cell therapies. As CEO of Rege Nephro he leads development of an ADPKD small molecule discovered using patient-derived iPSC disease models and directs a platform that differentiates iPSCs into kidney, liver, and pancreas lineages. He combines hands-on drug discovery experience from Astellas—where he led projects across oncology, immunology and translational medicine—with venture investing and board roles at JAFCO that helped take companies like Cuorips and Chordia public. His background uniquely spans antibody engineering, small molecules, medical devices, digital health and new business creation, supported by a PhD from the University of Tokyo and an MBA from Waseda. Known for bridging science and commercialization, he has shepherded mHealth tools into clinical guidelines and repeatedly moved early programs toward development candidates. Based in Kyoto, he brings a rare blend of deep lab expertise and venture-stage operational insight to building patient-focused therapeutics.
10 years of coding experience
12 years of employment as a software developer
MBA - Graduate School of Business and Finance, MBA - Graduate School of Business and Finance at WASEDA Business School
University of Tokyo
English, Japanese